GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...
GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...
Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV ... Its rival Pfizer (PFE) agreed as the New York ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback